INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) are fatal, neurodegenerative diseases of humans and animals and include Creutzfeldt-Jakob disease (CJD), GerstmannStraussler-Scheinker syndrome, Kuru, bovine spongiform encephalopathy (BSE), scrapie, transmissible mink encephalopathy and chronic wasting disease. At present, there is no treatment or cure.
The causative agent responsible for TSEs or prion diseases has yet to be fully defined. A fundamental event in disease is the conversion of the normal, detergent-soluble, proteinase K-sensitive isoform of the prion protein, PrP C , to an abnormal, detergent-insoluble, partially proteinase K-resistant isoform, PrP Sc , and the accumulation of this abnormal isoform in the central nervous system of infected animals (Hope et al., 1986; Meyer et al., 1986; Oesch et al., 1985) . The protein-only hypothesis suggested that no nucleic acid is needed for replication (Griffith, 1967) ; this has been refined by defining PrP Sc as the infectious agent and replication as the conversion by PrP Sc of host PrP C to more PrP Sc (Prusiner et al., 1982) . Although the mechanism of conversion is unknown, interaction between PrP C and PrP Sc is critically implicated by in vivo studies (Caughey & Chesebro, 1997) and features in the current models of replication such as template-assisted (Prusiner, 1991) and nucleation-dependent (Jarrett & Lansbury, 1993) conversion.
The in vitro cell-free conversion assay has provided a quick, simple and well-defined system in which to study the molecular factors that influence the transition of PrP C to PrP Sc (Kocisko et al., 1994) . In this system, PrP Sc , isolated from the brains of infected animals, induces the conversion of radiolabelled PrP C to a proteinase K-resistant isoform, PrP res . Newly formed PrP res is distinguished from the PrP used to seed the conversion by the fact that it is radiolabelled. The assay has been shown to replicate in vivo species specificity, strain properties and polymorphism barriers (Bessen et al., 1995; Bossers et al., 1997 Bossers et al., , 2000 Iniguez et al., 2000; Kocisko et al., 1995; Zhang et al., 2002; Raymond et al., 1997; Horiuchi et al., 2000) but as yet no in vitro-generated PrP res has been shown to be infectious .
Traditionally, cell-free conversion assays have used, as substrate, PrP C purified from mammalian tissue culture cells (Kocisko et al., 1994; Bossers et al., 2000; DebBurman et al., 1997; Saborio et al., 1999; Hill et al., 1999) or, more recently, from baculovirus-infected insect cells (Iniguez et al., 2000; Zhang et al., 2002) . In this study, we have modified the cell-free conversion assay by replacing the tissue culture-derived PrP C with PrP purified from bacteria and refolded in vitro. In addition, the guanidine conversion buffer, usually required for efficient conversion in vitro, has been replaced with a conversion buffer approximating physiological conditions, similar to that used by Horiuchi et al. (1999) .
We found that PrP derived from bacteria converts to a proteinase K-resistant isoform in the cell-free conversion assay and the assay was shown to mimic the in vivo species barriers of transmission of 263K hamster and 87V mouse scrapie between hamster and mouse.
With the emergence of BSE (Wells et al., 1987) and variant CJD (Will et al., 1996) , the search for prophylactic and therapeutic compounds is under way. We investigated the use of our modified cell-free conversion assay for identifying compounds that inhibit this conversion. Ten compounds with known anti-TSE activity in cell culture and/or in vivo were tested for their ability to inhibit this conversion. Eight of these compounds inhibited cell-free conversion to some extent, suggesting part of their in vivo effect could be modulated by binding directly to PrP. Two compounds did not inhibit in vitro conversion; these compounds may inhibit in vivo conversion indirectly by acting on some other part of cell metabolism.
These studies reinforce the specificity of PrP C and PrP Sc interactions and the utility of the cell-free conversion assay using bacterial recombinant PrP to investigate TSE transmission barriers and identify potential prophylactic compounds.
METHODS
Expression, radiolabelling and purification of recombinant PrP. Full-length mouse PrP of the Prn-p a genotype (Locht et al., 1986) with the N-terminal signal sequence replaced with methionine and the C-terminal signal sequence removed (corresponding to aa 23-230) was amplified from genomic DNA using the 59 and 39 primers 59-GGGATCCATCATGAAAAAGCGGCCAAAGCCTGGAG-39 and 59-CGAATTCTTAGGATCTTCTCCCGTCGTAATAG-39, respectively. Full-length hamster PrP (Basler et al., 1986) with the N-terminal signal sequence replaced with methionine and the C-terminal signal sequence removed (corresponding to aa 23-231) was amplified from genomic DNA using the 59 and 39 primers 59-GGGATCCATCATGAAGAAGCGGCCAAAGCCT-39 and 59-CGAATTCTCAGGACCTTCTTCC-39, respectively. Plasmid pTrcHis (Invitrogen) was digested with the restriction enzymes NcoI/EcoRI to remove the 6-histidine tag. PCR fragments were digested with restriction enzymes EcoRI/RcaI and ligated into the modified pTrcHis vector. Therefore, the recombinant vector encodes full-length, untagged PrP.
Calcium chloride-competent Escherichia coli strain 1B392 were transformed with the recombinant vectors. Cells were grown in 50 ml volumes in methionine-deficient M63 media containing ampicillin to an OD 600 (Jackson et al., 1999) and dialysis into 50 mM sodium acetate (pH 5?5). Estimates of PrP purity were made by Coomassie staining and estimates of concentration were made using dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA, Perkin-Elmer) using unlabelled recombinant PrP as a standard, the mAb FH11 (TSE Resource Centre, I.A.H., Compton, UK) for capture of PrP onto a 96-well plate and europium-labelled mAb 6H4 for subsequent detection.
PrP
Sc preparation. PrP Sc was prepared from the brains of terminally ill 87V-infected VM mice and 263K-infected hamsters, based on a method described by Hope et al. (1986) . Briefly, a 5 % (w/v) brain homogenate was prepared in 10 mM sodium phosphate (pH 7?4) and 10 % (w/v) N-lauryl sarcosinate. The suspension was centrifuged at 22 000 g for 30 min at 10˚C. The supernatant was centrifuged at 215 000 g for 150 min at 10˚C and the pellet resuspended in H 2 O. The volume of the solution was adjusted to 9 ml g 21 of brain and its ionic composition to 0?6 M potassium iodide, 6 mM sodium thiosulphate, 1 % (w/v) N-lauryl sarcosinate and 10 mM sodium phosphate (pH 8?5) and centrifuged at 285 000 g for 90 min at 10˚C through a sucrose cushion of 20 % (w/v) sucrose in 0?6 M potassium iodide, 6 mM sodium thiosulphate, 1 % (w/v) N-lauryl sarcosinate and 10 mM sodium phosphate (pH 8?5). The pellet was washed in H 2 O and centrifuged in a microfuge. The final PrP Sc pellet was resuspended in H 2 O by sonication to approximately 1 mg ml 21 .
Cell-free conversion assay. Two cell-free conversion protocols were used in this study, either with or without guanidine. The cellfree conversion assay without guanidine was based on that used by Horiuchi et al. (1999) . Briefly, PrP Sc was sonicated and approximately 1 mg incubated with 200 ng of [
S]PrP in conversion buffer
[50 mM citrate (pH 6?5), 50 mM potassium chloride, 10 mM magnesium chloride, 100 mM sodium chloride and 0?1 % (v/v) Nonidet P-40], either with or without compounds to be tested for inhibition, for 24 h at 37˚C in a 20 ml volume reaction. Following incubation, 20 ml H 2 O was added. One-twentieth of the reaction mixture was removed for analysis without proteinase K treatment and the rest was treated with 60 mg proteinase K ml 21 for 1 h at 37˚C. Proteinase K digestion was stopped by the addition of Pefabloc to 1 mM. All samples were precipitated with 20 mg BSA and 4 vols icecold methanol at 220˚C. The resulting pellet was boiled for 10 min in SDS-PAGE sample buffer and analysed by SDS-PAGE in 15 % polyacrylamide gels. Gels were then fixed, dried and exposed to film. Autoradiographs were quantified using Phoretix Gel Analysis software. For cell-free conversion assays in guanidine buffers, we based our method on that described in Kocisko et al. (1994) . PrP Sc was sonicated briefly and approximately 1 mg pre-incubated in 2 M guanidine, 0?25 % (w/v) zwittergent 3-14 and 50 mM citrate (pH 6?5) in a reaction volume of 10 ml for 2 h at 37˚C. Following pre-incubation, 200 ng [ 
RESULTS

Production of 35 S-labelled PrP in recombinant bacteria
Recombinant mouse PrP (aa 23-230) was expressed in bacteria from the modified pTrcHis expression vector in the presence of [
35 S]methionine. Following purification and refolding in vitro, the recombinant protein was analysed by Western blotting with anti-PrP mAb (Fig. 1, lane 1) and Coomassie staining (Fig. 1, lane 2) . The protein had a molecular mass of approximately 26 kDa, as expected for unglycosylated PrP lacking the glycosylphosphatidylinositol (GPI)-anchor addition peptide. The yield was approximately 100 mg [
35 S]MoPrP (recombinant mouse PrP) per 50 ml of culture medium and purity was estimated by Coomassie staining to be approximately 95 %. Mass spectrometry and circular dichroism spectroscopic analysis of unlabelled protein confirmed the correct expression, formation of the disulphide bond and folding into a normal a-helical formation (data not shown).
Conversion of bacterial PrP to PrP res
PrP C purified from mammalian tissue culture cells (Kocisko et al., 1994; Bossers et al., 2000; DebBurman et al., 1997; Saborio et al., 1999; Hill et al., 1999) and from baculovirusinfected insect cells (Zhang et al., 2002; Iniguez et al., 2000) has been used as substrate in the cell-free conversion assay. In this study, recombinant PrP, purified from bacterial cells and refolded in vitro, could also be converted into a proteinase K-resistant form in the cell-free conversion assay. Recombinant mouse PrP, MoPrP, was radiolabelled during expression, purified from bacteria and refolded in vitro. [
S]MoPrP was incubated with and without unlabelled PrP
Sc , isolated from 87V scrapie-infected VM mouse brains in a guanidine-free conversion buffer at 37˚C for 24 h. (Fig. 2, lane 4) but not in the absence (Fig. 2, lane 2) (Oesch et al., 1985; Hope et al., 1986) . The efficiency of the conversion was approximately 30 %, according to densitometric analysis of labelled PrP before and after proteinase K treatment. This result indicates that recombinant PrP (Fig. 2) , although, in vivo, mice with the Prn-p a genotype rarely if ever develop neurological disease following exposure to the 87V (VM) strain of mouse scrapie (M. E. Bruce, IAH, Edinburgh, UK, personal communication). However, this is only an apparent breakdown in the correlation between the cellfree conversion efficiency and in vivo transmissibility, since, while Prn-p a allotype mice rarely develop clinical signs, 87V scrapie readily replicates in their brains and spleens. Furthermore, pathology typical of brain scrapie has been found in some older mice dying of 'natural causes', suggesting that 87V-infected Prn-p a mice have prolonged survival times rather than a resistance to disease (M. E. Bruce, IAH, Edinburgh, UK, personal communication).
Species specificity in the conversion reaction
87V mouse scrapie has a prolonged incubation time in hamsters and mice are highly resistant to infection with 263K hamster scrapie. To determine whether our cell-free conversion assay mimics this in vivo species specificity, hamster and mouse PrP were radiolabelled and purified from the bacterial expression system, refolded in vitro and incubated in a non-guanidine conversion buffer, with PrP Sc isolated from 263K-infected hamster brains and 87V-infected mouse brains in homologous and heterologous conversion assays. (Fig. 3, lane 8) . These data indicate that the species specificity observed in vivo can be mimicked in our cell-free conversion assay using recombinant bacterial PrP.
Inhibition of the cell-free conversion assay
There are several lead anti-TSE compounds, including CR, chlorpromazine and quinacrine (reviewed by Gilbert & Rudyk, 1999) . CR inhibits PrP res formation in scrapieinfected mouse brain cells (SMB) (Rudyk et al., 2000) , in the cell-free conversion assay and in scrapie-infected neuroblastoma cells (ScN2a) (Demaimay et al., 1998 (Demaimay et al., , 2000 Caughey & Race, 1992; Caughey et al., 1993) and can cure these cells of infectivity. CR also prolongs the survival time of scrapie-infected hamsters if administered around the time of experimental infection (Ingrosso et al., 1995) . Although CR has anti-TSE activity, it has poor blood-brain barrier permeability and is toxic when broken down in the gut by microbes (Boss et al., 1987) ; therefore, its use as a drug is limited and structure activity studies have been carried out to improve its therapeutic properties (Rudyk et al., 2000; Demaimay et al., 1998) . Chlorpromazine and quinacrine have been used in humans for many years as anti-psychotic and anti-malarial drugs, respectively, and have been shown to inhibit PrP res formation in ScN2a cells (Korth et al., 2001; Doh-Ura et al., 2000) . Although these drugs have anti-TSE activity, their mechanisms of action are unknown.
We investigated the use of our cell-free conversion assay, using bacterial PrP, to study the inhibitory effect of such anti-TSE compounds. CR and its analogues and chlorpromazine and quinacrine (Fig. 4) were tested for their ability to inhibit formation of PrP res in our non-guanidine cell-free conversion assay using recombinant PrP purified from bacteria and refolded in vitro. [
S]MoPrP was incubated with 87V PrP
Sc with varying amounts of inhibitor compounds in the cell-free conversion assay. Fig. 5 (Fig. 6) . Compound III was the least effective inhibitor, with an average IC 50 of 400 mM. As has been reported elsewhere (Demaimay et al., 1998 (Demaimay et al., , 2000 Rudyk et al., 2000) that at low concentrations, CR and its analogues enhanced conversion above the control level. Chlorpromazine and quinacrine did not inhibit conversion at concentrations of 0?1-100 mM in our cell-free conversion assay (data not shown).
These data indicate that CR and its analogues may inhibit in vivo conversion by binding directly to PrP, whereas chlorpromazine and quinacrine may inhibit in vivo conversion not by binding to PrP but by influencing some other event in the cell.
Guanidine prevents the inhibitory effect of CR
Previously, the inhibitory effects of CR and its analogues on the cell-free conversion of recombinant PrP C were investigated using protocols that incorporated guanidine (Demaimay et al., 1998 (Demaimay et al., , 2000 . Although CR inhibits conversion of PrP C to PrP res under such conditions, we wanted to measure the effect of CR on conversion without contributions from such non-physiological salts. The efficiency of conversion of [ 35 S]PrP was similar in both the presence and the absence of guanidine (Fig. 5a, lane 2, and Fig. 7, lane 2, respectively) . However, when our more physiologically compatible conversion buffer was substituted with conversion buffer containing guanidine, CR no longer inhibited cell-free conversion at similar concentrations (Fig. 7) . Kocisko et al. (1994) were the first to demonstrate that PrP Sc could induce the conversion of PrP C into a proteinase K-resistant isoform, PrP res , a hallmark of the disease-specific prion protein, in an in vitro cell-free assay and that this PrP res was capable of limited self propagation. Their study used recombinant PrP C immunoprecipitated from mammalian cell culture as the substrate for conversion (Kocisko et al., 1994) and although PrP C and PrP Sc are the main constituents of the cell-free conversion assay, it is possible that cellular factors or antibody fragments introduced during the immunoprecipitation may co-purify with PrP C and influence the cell-free conversion assay; chaperones (DebBurman et al., 1997), metal ions (McKenzie et al., 1998) and cell lysates (Saborio et al., 1999) have all been shown to enhance conversion. In addition, the production of eukaryotic protein is time consuming and requires large amounts of radioactivity for low yields of radiolabelled protein.
DISCUSSION
Recently, recombinant PrP isolated either by immunoprecipitation (Iniguez et al., 2000) or using an histidine tag (Zhang et al., 2002) from baculovirus-infected insect cells has been used as a substrate in the cell-free conversion assay. These studies indicate that a non-mammalian source of PrP can be converted into a proteinase K-resistant species. In this study, we have used recombinant PrP expressed and purified from bacteria and refolded in vitro as a substrate in the cellfree conversion assay. This system uses relatively low amounts of radioactivity to produce high yields of recombinant protein, devoid of either an epitope tag or an histidine tag that may influence conversion, and because the protein is purified biochemically, complications such as the potential co-purification of cellular factors or antibody fragments is reduced. In addition, it is a quick and simple procedure and can allow rapid variation of protein sequence using standard cloning and mutagenesis techniques. Fulllength mouse PrP (aa 23-230) was expressed, radiolabelled and purified from bacteria and refolded in vitro. The titres ±SE were calculated from dose response curves from three independent experiments. expressed protein had a molecular mass of approximately 26 kDa, characteristic of full-length, aglycosyl PrP lacking the GPI anchor. Kocisko et al. (1994) have demonstrated that PrP does not require glycosylation or a GPI anchor to be converted in their cell-free conversion assays. We were able to show that bacterial recombinant PrP can be converted into PrP res in the cell-free conversion assay with efficiencies of conversion similar to those obtained with mammalian and baculovirus recombinant PrP. The most abundant [
S]PrP
res product of the cell-free conversion assay is 17 kDa, 6-7 kDa smaller than the precursor [
35 S]PrP. This is similar to the 6-7 kDa reduction in mass seen upon digestion of brain-derived PrP Sc . Proteinase K-resistant species smaller than 17 kDa were frequently observed in cell-free conversion assays. These smaller species do not correlate with in vivo transmissibility and may represent by-products of a non-pathogenic folding pathway.
To validate this bacterial PrP conversion assay, we investigated if the in vivo transmissibilities of scrapie between hamster and mouse could be replicated in this assay. The barriers of transmission of TSEs from one species to another generally involve a prolonged incubation period. The species specificity observed in vivo has been reproduced in the cellfree conversion assay using mammalian (Kocisko et al., 1995; Raymond et al., 1997; Horiuchi et al., 2000) and baculovirus (Iniguez et al., 2000; Zhang et al., 2002) recombinant PrP. In this study, the results of conversion reactions between recombinant hamster and mouse PrP, and PrP Sc of 263K hamster and 87V mouse, correlates with the relative transmissibility of scrapie between those species in vivo. Although molecular compatibility between PrP C and PrP Sc is important in the transmission of TSEs, other factors such as dose, route of infection and strain of agent may influence conversion in vivo.
Chlorpromazine, quinacrine and CR (and its analogues) are known inhibitors of PrP res formation in tissue culture cells (Korth et al., 2001; Demaimay et al., 1998 Demaimay et al., , 2000 Rudyk et al., 2000; Caughey & Race, 1992; Caughey et al., 1993) and have shown limited success in vivo (Ingrosso et al., 1995) . We observed similarities and differences in the ability of these compounds to inhibit conversion in the bacterial PrP cellfree assay. Chlorpromazine and quinacrine, contrary to their inhibitory effects on PrP res formation in ScN2a cells (Korth et al., 2001) , did not inhibit PrP res formation in the cell-free conversion assay. This suggests that in vivo chlorpromazine and quinacrine inhibit conversion not by binding directly to PrP but in some less direct effect on the cell. A recent study investigating the efficacy of quinacrine in an in vivo model of mouse-adapted scrapie failed to show a significant increase in survival time of scrapie-infected mice following quinacrine administration (Collins et al., 2002) . Alternatively, this lack of effect in the cell-free conversion assay may be due to host and TSE strain variables that are known to influence the effectiveness of anti-TSE drugs in vivo. The CR analogues used in our cell-free conversion assay were screened previously for their ability to inhibit PrP res formation in SMB cells (Rudyk et al., 2000) . Although the IC 50 titres reported in the cellular assay were not identical to the titres generated in the cell-free system, the order of effectiveness as inhibitors was the same. In summary, SR was the most potent inhibitor in both assays. The half molecule of CR had some activity but only at high concentrations. Compounds with an increased level of sulphation, substitution of the naphthelene amino with trifluoroacetamide, 3,39-modification of the biphenyl or replacement of the biphenyl with bisulphone, all retained some activity. This suggests that it is possible to modify the structure of CR without dramatically affecting its activity as an inhibitor and therefore, it should be possible to design a compound with improved pharmacokinetic properties. The correlation between the cell-free and the cellular conversion assays suggests that in vivo CR may prevent conversion by binding directly to PrP. The enhancement of PrP res formation observed at low concentrations of CR requires further investigation due to the obvious therapeutic implications.
The presence of guanidine in the conversion buffer prevented the inhibition of conversion by CR. This contradicts data that demonstrate inhibition of conversion by CR in the cell-free conversion assay in guanidine buffer (Demaimay et al., 1998 (Demaimay et al., , 2000 . Reasons for the observed difference may be the source of recombinant PrP, the species of PrP or other experimental conditions. However, the physiological conditions of our conversion assay give more relevance to the assay as a model of conversion and the similarity between our in vitro data and those from cell culture experiments (Rudyk et al., 2000) support the use of more physiologically compatible buffers.
In summary, we have demonstrated that recombinant PrP expressed in a bacterial system and refolded in vitro can be converted into PrP res . In addition, the assay was shown to mimic the in vivo species specificity of transmission of 263K hamster and 87V mouse scrapie between hamster and mouse and will allow the study of TSE transmission barriers. Together, the correlation between the cell-free and the cellular conversion assay in the inhibitory effects of anti-TSE compounds, and the use of a physiologically compatible conversion buffer, make the conversion assay using bacterial recombinant PrP a promising model for discovering and investigating potential prophylactics.
